53
Successful Drug Discovery Informed by Actinobacterial Systematics Michael Goodfellow, School of Biology, Newcastle University, Newcastle upon Tyne Newcastle University V. maris AB-18-032 T S. leeuwenhoekii C34 T

Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Successful Drug Discovery Informed by

Actinobacterial Systematics

Michael Goodfellow, School of Biology,

Newcastle University, Newcastle upon Tyne

Newcastle

University

Abyssomicins

Structures of Abyssomicins Biological activityHPLC-DAD analysis of culture filtrateextract Antibacterial activity (MIC):

Growth inhibition of Gram-positive bacteria

Staphylococcus aureus (MRSA) 4 µg/ml

Staphylococcus aureus (iVRSA) 13 µg/ml

Mode of action:

inhibitior of pABA biosynthesis

covalent binding to Cys263 of PabB

(4-amino-4-deoxychorismate synthase) by

Michael addition D

C

B

CH3H3C

O

OO

HO

CH3

O7

O

CH3H3C

O

OO

HO

CH3

O7

O

CH3H3C

O

OO

HO

CH3

OO

N

HO

CH3H3C

OO

HO

CH3

OO

HO

CH3H3C

O

OO

HO

CH3

OO

NHO

CH3H3C

O

OO

HO

CH3

OO

G H

atrop-C

min2 4 6 8 10 12 14 16

mAU

0

100

200

300

400

500

C

AB

DAD1 G, Sig=435,40 DAD1 F, Sig=360,40

DAD1 C, Sig=260,20

DAD1 A, Sig=210,10

DAD1 D, Sig=280,20 DAD1 , Sig=310,20

DAD1 H, Sig=500,40

DAD1 B, Sig=230,10

Pro

xim

icin

A

nm300 400 500

mAU

0

50

100

150

200

250

DAD1, 7.446 (300 mAU,Dn1) of 002-0101.D

Rt 7.5 min

atrop-C

nm300 400 500

mAU

0

25

50

75

100

125

150

175

DAD1, 7.382 (196 mAU,Up2) of 002-0101.D

CRt 7.4 min

Verrucosispora

maris AB-18-032

Sea of Japan

-289 m

V. maris AB-18-032T

S. leeuwenhoekii C34T

Page 2: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Atacama Desert

Actinobacteria from Atacama Desert

In This Talk I will Consider:

• Actinobacteria as a key group in the search for new therapeutic drugs.

• Taxonomic approaches to the selection of actinobacteria from extreme habitats.

• Atacama desert soil as a source of creative actinobacteria.

• Selection of novel actinobacteria for chemical screening.

• Conclusions and some new directions of travel.

Page 3: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

3

Need for a New Generation of Antibiotics

2008-2012

New antibacterial agents approved by the Food and Drug Administration

(FDA) in the United States between 1983-2009.

Adapted from Bassetti et al. (2011).

Page 4: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Drug Target Sample extracts

Dereplication Filters

H I T

Compound Evaluation &

Characterization

New

Biological

Material

Novel

Screens

L E A D

Twin Track Approach

Goodfellow & Fiedler (2010). Antonie van Leeuwenhoek 98:119-142.

Page 5: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Actinobacteria

What are they?

• A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have

DNA rich in guanine plus cytosine (> 55% mol. GC), unique 16S and 23S rRNA signatures and conserved

indels in some proteins.

Why prioritize them for drug discovery?

• Unravelled capacity to synthesize natural products with a wide spectrum of bioactivity.

• Account for almost half of all microbial bioactive compounds; nearly 80% produced by Streptomyces

strains.

• Culture-independent studies show that <1% of actinobacterial taxa in natural habitats have been cultivated

hence scope for the discovery of new chemical entities from cultivable novel taxa is enormous.

• Diverse populations of novel actinobacteria present in extreme habitats are able to produce new specialised

metabolites.

Page 6: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Whole Genome Sequence of Streptomyces coelicolor Strain A3 (2)

Contains 27 natural product biosynthetic gene clustersHopwood et al., 2002. Nature 417:141-147.

Page 7: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Specialised Metabolites produced by Streptomyces coelicolor A3(2)

(cultivated in R2 for 5 days)

Actinorhodin

∆act ∆red

Prodiginine

Actinorhodin

Prodiginine

1955 / Actinorhodin

1980 / Undecylprodigiosin

1978 / Calcium Dependent Antibiotic1976 / Methylenomycin(SCP1 encoded)

We do a poor job in

interpreting a cell’s potential

from its genomic sequence.

However, we are getting

better.

Page 8: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Prokaryotic Systematics is not a Luxury

8

Prokaryotic systematics is a core discipline practiced by few. However, the implementation of

taxonomic concepts and practices underpins taxonomic approaches to drug discovery:

• Well delineated natural classification.

• Provision of a stable, universally accepted nomenclature.

• Establishing cultivable actinobacterial diversity in natural habitats.

• Improved procedures for selective isolation of novel and neglected taxa.

• Rational choice of strains for bioprospecting and biotechnology.

• Inferring the course of prokaryotic evolution.

• Legislation (e.g. Hazard groups, patents of living biological material, Convention on

Biological Diversity).

Page 9: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Integrated use of genotypic and phenotypic data:

Chemotaxonomy

Genomics

Molecular Systematics

Numerical Taxonomy

Outcomes:

Sound infrastructure for pure and applied microbiology and for designing and implementing

scientific policies.

Polyphasic Taxonomy

1960-2014

9

Polyphasic Taxonomy =Sound Classification

Stable Nomenclature

Reliable Identification

Page 10: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Phylum Actinobacteria

5 Classes

19 Orders

50 Families

220 Genera

3,000 Species

Hierarchic Classification of Actinobacteria based on Phylogeny

Goodfellow et al. 2012. Bergey’s Manual of Systematic Bacteriology, 2nd Edition, Volume 5, Springer, New York.

Bergey’s Manual Trust is

a nonprofit organisation

that is supported by

royalty income.

The next edition of

Bergey’s Manual will be

an electronic one that will

be frequently updated.

Page 11: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Our Strategy

Extreme/Neglected habitats

Selective isolation

Selection of isolates

Dereplication technologies

Novel actinobacteria

Commercial success

Screening

Dereplication of active compounds

New natural products

Culture-dependent bioprospecting strategy

Current bottleneck

• Recent approaches to drug discovery (eg.

combinatorial chemistry and fragment based

drug design) have yet to make a significant

impact.

• Need to screen novel actinobacteria to avoid

costly rediscovery of known bioactive

compounds.

Page 12: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Why Focus on Actinobacterial Diversity from Extreme

Habitats?

• Isolation of actinobacteria from extreme biomes rests on the premise that

harsh environmental conditions give rise to unique taxa (species, genera) with

novel chemistry.

• Evidence of a coupling between taxonomic and chemical diversity means that

taxonomic diversity can be used as a surrogate for chemical diversity.

• Screening common actinobacteria from well studied habitats leads to the

costly rediscovery of known bioactive compounds

Decrease in the number of new drugs coming onto the market

http://smellslikescience.com/a-need-for-new-antibiotics/

Page 13: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Actinobacteria for Low Throughput Screens

Objectives:

Focus on rare and previously unknown taxa, including novel species of Streptomyces.

Key taxonomic methods designed to meet these aims:

• Choice of selective isolation procedures.

• Selection of cultivation media.

• Recognition of novel taxa by comparative sequencing of conserved genes / proteins, notably 16S

rRNA genes.

Screening strategies:

• Cell based targets- plug assays using panel of pathogenic strains.

• Reporter Bacillus subtilis strains to detect cellular targets.

• Choice of production media.

• Chemical analysis of extracts for novel specialised metabolites.

Discovery dependent on dereplication at all stages of the procedure.

Page 14: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Atacama Desert

The Atacama Desert located in northern

Chile is the oldest and driest desert on the

planet.

Most Atacama Desert soils and regoliths are either hyper-

arid (ratio of mean annual rainfall to mean annual

evaporation is < 0.05) , or extreme hyper-arid

(corresponding ratio < 0.002).

Low concentrations of organic matter, high salinity, the

presence of inorganic oxidants and high UV radiation

conditions.

The underlining premise is that these extreme conditions

will have given rise to a unique actinobacterial diversity and

consequential chemical diversity.

ALMALomas Byas

Yungay

Salar de

Atacama

Page 15: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Sampling Sites

Salar de Atacama

Hyper-arid area

YungayExtreme hyper-arid area

ALMA

High altitudes, Very high UV radiation

Lomas Bayas

Most extreme hyper arid area

Page 16: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Selective Isolation of Actinobacteria

16

Media Selective agents Target organism (s) References

Glucose-yeast extract

agar

Rifampicin (20µg ml-1) Actinomadura spp. Athalye et al. (1981)

Gause’s No.1 agar Nalidixic acid (10µg ml-1) Rare or uncommon

actinomycetes

Zakharova et al. (2003)

Humic acid-vitamin agar Humic acid (1g/L) Streptosporangiaceae

spp.

Hayakawa & Nonomura

(1984)

Oligotrophic agar Low carbon and nitrogen

sources

Rare actinomycetes Busarakam (2013)

Raffinose-histidine agar Common Streptomyces spp. do

not grow well in the presence

of these nutrients

Rare or uncommon

streptomycetes

Vickers et al. (1984)

Starch-casein agar High carbon to nitrogen ratio Streptomyces spp. Küster and Williams (1964)

SM1and SM2* agars Neomycin (4 µg ml-1), D(+)

sorbitol (1%, w/v)*

Amycolatopsis spp. Tan et al. (2006)

Cycloheximide and nystatin (each at 25 µg ml-1) used to control fungi.

Page 17: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Selective Isolation

Range of selective isolation media

Sprinkle plates Dilution plates

Page 18: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Isolation of Streptomyces Strains

Page 19: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Isolation of Amycolatopsis Strains

SM 1 agar

Oligotrophic agar

Starch-casein vitamin agar

Humic-acid-vitamin-agar

Page 20: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Isolation of Modestobacter StrainsArginine-vitamin agar

Starch-casein-vitamin agar

Humic-acid-vitamin agar

Oligotrophic agar

R2A agar

Page 21: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Actinobacteria (cfu/g dry weight soil) growing on Selective Media

inoculated with Suspensions of Atacama Desert Soils and Incubated at 28oC for 3 Weeks

Soil

Media

Gause’s No.1 Humic acid agar

Oligotrophicagar

Starch-casein agar

SM1 agar

Salar de Atacama

1.1x104 1.3x104 0.3x102 0.1x102 0.3x102

Yungay 3x102 5x103 3.3x102 2.3x102 4.7x102

Actinobacteria were not isolated on glucose-yeast extract or raffinose-histidine agars.

Page 22: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Dereplication

Term used for differentiating phenotypically similar isolates (and metabolites) to

select representatives to facilitate efficient screening and to minimize costs and

time in maintaining large culture collections.

• Choice of methods:

Chemical: fatty acid analyses, pyrolysis and MALDI-TOF mass spectrometry.

Molecular: rep-PCR, genus specific primers, multilocus sequence analysis and

16S rRNA and whole-genome sequencing.

Morphology: use of predictive colonial features (colour-grouping).

• Outcome:

Significant increase in hits.

Page 23: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Colour-grouping

Production of melanin pigments

Antony-Babu et al. (2010). Antonie van Leeuwenhoek 97, 231-239.

Page 24: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Colour-grouping of Streptomyces isolates from Salar de Atacama and Yungay Soils

Growth on oatmeal agar Strain numbers and source of isolates

Colour group

code

Aerial spore

mass pigment

Substrate

mycelial colour

Colour of

diffusible

pigment

Salar de Atacama Yungay

Code Code

KNN11 yellowish white yellowish white none G18-1 (63a), G18-2 (74a),

G18-3 (149c), G18-4

(155b), G52 (62a) nd

G91(a)

-

KNN23 yellowish white deep orange yellow gray yellow none ASC2b, KB111b

KNN48 yellowish white light orange yellow light orange yellow G14-1 (57c), G14-2 (65a),

G14-3 (257e), G14-4

(258e), G14-5 (259e) and

G14-6 (260e)

KB1d, KB2d, KB8d,

KB13d,

None of the isolates produced melanin pigments on peptone-yeast extract-iron agar.

174 out of 224 representatives of the genus Streptomyces isolated from the hyper-arid Salar de Atacama soil (71%)

were assigned to 36 multi- and 11 single-membered colour- groups (82.3% of isolates).

58 out of 105 representatives of the genus Streptomyces isolated from Yungay soil (55.2%) were assigned to 8 multi-

and 5 single-membered colour-groups (22.8% of isolates).

The remaining isolates was assigned to colour-groups containing isolates from both locations.

Page 25: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Colour-grouping of Isolates from ALMA soils

Aerial spore mass colour Substrate mycelial colour Diffusible pigment Melanin production Strains

Yellow white Dark yellow brown - - H9, H39

Yellow white Pale orange yellow - - H45

Assignment of isolates from ALMA soil samples to colour-groups based on growth on oatmeal and

peptone-yeast extract-iron agar plates incubated at 28oC for 14 days.

Multi-membered colour-group

Single-membered colour-group

Isolate H9

ALMA subsurface soil sample 4 at 4000 m above sea level.

Isolate H45

ALMA subsurface soil sample 6 at 5000 m above sea level.

•113 representative strains isolated from the ALMA sites were assigned to 9 multi- and 57

single-membered colour-groups.

Page 26: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Oatmeal agar PYEIA Strains

Aerial spore mass colour Substrate mycelial colour Diffusible pigment Melanin

production

Dark gray Gray orange Pale green yellow - LB55, LB60

White Dark purple gray & Black Blackish purple - LB63

LB55 isolated from Lomas Bayas LB63 isolated from Lomas Bayas

Colour-grouping of Isolates from

Lomas Bayas soil

Assignment of isolates from the Lomas Bayas soil sample to colour-groups based on growth on

oatmeal and peptone-yeast extract-iron agar plates incubated at 28oC for 14 days.

Multi-membered colour-group

Single-membered colour-group

•52 representative strains isolated from Lomas Bayas soil were assigned to 9 multi- and 26

single-membered colour-groups.

Page 27: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Agar Plug Assays

Isolate C38

Starch-casein isolation plate

Page 28: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Zones of Inhibition (mm in diameter) produced by Representative Novel Streptomyces Strains isolated from ALMA and Salar de Atacama Soils

Isolates Bacillus

subtilis

Escherichia

coli

Pseudomonas

fluorescens

Staphylococcus

aureus

Saccharomyces

cereviseae

ALMA

H9 16 12 18 - 18

H45 12 14 15 - 22

H71 13 11 19 12 32

Salar de Atacama

KNN26 18 17 12 24 22

KNN35-1 24 20 20 28 25

KNN90 22 16 22 25 24

113 representatives isolated from ALMA soils were screened; 6 showed activity against

all 5 pathogens and 77 (68%) activity against at least one of the pathogenic strains.

121 representatives of the Salar de Atacama colour-groups were screened and 72 (60%)

showed activity against at least one of the pathogenic strains.

Page 29: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Zones of Inhibition (mm in diameter) produced by Representative Novel

Streptomyces strains isolated from Hyper-Arid Salar de Atacama Soil against Bacillus subtilis Reporter Strains

Isolates Cell envelope

synthesis

Cell wall

synthesis

DNA

synthesis

Fatty acid

synthesis

RNA

synthesis

G9-5 13 10 15 14 17

G10-1 9 8 10 10 10

G10-5 18 12 15 16 15

G16-1 7 2 10 8 8

G36-1 13 11 15 14 12

G64 10 9 19 12 10

This approach is based on cells that carry -galactosidase genes bound to promotors

that specifically respond to certain types of antibiotics (Fischer et al. 2004, Genome

Research 14:90-98).

Page 30: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Actinomadura rifamycini IFO 14183T(U49003)

Isolate G4-15 (Cell wall)

Isolate BA8 (Cell wall)

Isolate B45 (Cell wall)

Isolate B68 (Cell wall)

Actinomadura apis IM17-1T(AB557596)

Actinomadura cremea JCM 3308T(AF134067)

Actinomadura yumaensis JCM 3369T (AF163122)

Actinomadura livida JCM 3387T(AF163116)

Actinomadura sputi IMMIB L-889T (FM957483)

Actinomadura vinacea JCM 3325T(AF134070)

Actinomadura rugatobispora IFO14382T(U49010)85

53

ME

100

*

*

99

0.002

*

99

100ME

ME

ME50

Novel Actinomadura isolates from the hyper-arid

Salar de Atacama soil

30

Page 31: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

N. candida HMC10T(DQ285421)

N.rubra DSM 43768T(AF277200)

N. turkmeniaca DSM 43926T(AF277201)

N. antimicrobica YIM 61105T(FJ157184)

Isolate BA6 (Cell wall & Cell envelope)

Isolate B37 (Cell wall & Cell envelope)

N. salmonea DSM 43678T(X97892)

N. endophytica YIM 65601T(GU367158)

N. maritima FXJ7.203T(GU002054)

60

69

ME

64

ME

*

0.002

45

*

*

75

72

31

Novel Nonomuraea isolates from the hyper-arid

Salar de Atacama soil

Page 32: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

S. flavidoviresns subclade

S. michigannensis subclade

S. thioluteus subclade

S. albus subclade

S. macrosporus subclade

KNN89 (KB208 edit)

S. nanhaiensis subclade

S. radiopplugnans subclade

S. somaliensis DSM 40738T (AJ007403)

S. griseosporeus NBRC 13458T (AJ781333)

S. glomeratus LMG 19903T (AJ781754)

S. chiangmaiensis suclade

S. lannensis TA 4-8T (AB562508)

S. griseocarnatus subclade

KNN2-4 (G11-4 edit)

Streptomyces new subclade

S. speibonae PK-BlueT (AF452714)

S. parvulus subclade

S. albogriseolus subclade

S. lusitanus subclade

S. atrovirens NRRL B-16357T DQ26672

S. glaucus subclade

S. aurantiogriseus subclade

S. djkartensis NBRC 15409T AB184657

S. carpinensis NBRC 12414T AB184574

S. viridiviolaceus subclade

S. caecalis subclade

KNN42 (AT17 edit)

KNN35-1 (G34-1 edit2)

KNN35-2 (G34-2 edit2)

S. braxilliensis subclade

KNN64-5 (G8-5 edit)

KNN38-1 (G7-1 edit)

C59

KNN26 (G79 edit)

KNN13 (AT5 edit)

S. fimbriatus NBRC 15411T (AB184659

99

95100

83

5193

96

68

98

99

94

95

88

97

83

96

52

90

94

58

89

83

50

89

0.002

Novel Streptomyces isolated from the hyper-arid Salar de Atacama soil

C38

C34

C79

C58

Isolate C38

S. lannensis TA4-8T

S. chiangmaiensis TA4-1T

S. chromofuscus NBRC 12851T

S. speibonae PK-BlueT

S. griseoincarnatus LMG 19316T

S. erythrogriseus LMG 19406T

S. albogriseolus NRRL B-1305T

S. viridodiastaticus NBRC 13103T

S. longispororuber NBRC 13488T

S. thermocarboxydus DSM 44293T

S. lusitanus NBRC 13484T

S. coeruleorubidus NBRC 12844T

S. coerulescens ISP 5146T

S. spinoverrucosus NBRC 14228T

S. lomondensis NBRC 15426T

S. parvulus NBRC 13193T

S. hyderabadensis OU-40T

S. leeuwenhoekii C34T

S. somaliensis DSM 40738T

S. griseosporeus NBRC 13458T

S. glomeratus LMG 19903T

S. mexicanus CH-M-1035T

S. albus subsp. albus NRRL B-2365T

100

100

100

74

86

63

0.005

Bar 1 µ

Page 33: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Phylogenetic tree inferred from concatenated

partial sequences of the house-keeping genes atpD,

gyrB, recA, rpoB and trpB in MEGA 5.2 (Tamura et

al., 2011) using the maximum-likelihood method

based on the General Time Reversible model (Nei

& Kumar, 2000).

Isolate KNN41

Isolate KMM11-1

Isolate KNN11-5

Isolate KNN9-3

Isolate KNN6-6

Isolate KNN6-9

Isolate C38 (atacamycins)

Isolate C58 (novel cyclic lasso peptides)

Isolate C79 (four new specialised metabolites)

Isolate KNN10-5

Isolate KNN25

Isolate KNN10-4

Isolate KNN48-1

Isolate KNN24-1

Isolate KNN2-6

Isolate C34 (chaxamycins)

61

60

0.0002

Streptomyces sp. C38

Streptomyces sp. C59

Streptomyces sp. C79 Streptomyces leeuwenhoekii 16S rRNA gene clade

S. leeuwenhoekii

Putative new species

Page 34: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

SM 1 agar

Oligotrophic agar

Starch-casein vitamin agar

Humic-acid-vitamin-agar

Members of Amycolatopsis methanolica 16S rRNA gene clade isolated from hyper-arid

Salar de Atacama soil

Selective mediaKNN50-11KNN50-16KNN50-9KNN61-1

A. thermalba SF45T (HQ668525)KNN50-17KNN50-13KNN50-10KNN50-4KNN50-2KNN50-1KNN49-12KNN49-11KNN49-6A. granulosa GY307T (AF466101)

A. viridis GY115T (AF466095)

A. thermoflava N1165T (AF052390)

A. methanolica 239T (AQUL01000001)

A. eurytherma NT 202T (AJ000285)

A. tucumanensis ABOT (DQ886938)

A. thermophila GY088T (AY129774)

A. endophytica KLBMP 1221T (HM153799)

A ruanii NGM112T HQ668524

KNN50-18

KNN50-14

KNN50-6

KNN49-3

KNN49-5

KNN49-26

KNN50-7

KNN50-8

KNN49-10

KNN49-1

KNN50-5

KNN50-13

KNN50-15

GY024

GY142

A. orientalis subsp. orientalis IMSNU 20058T (AJ400711)

Actinokineospora riparia NRRL B-16432T (AF 114802)

100

100

87

66

100

99

53

99

0.005

*

*

*

**

***

**

*

Page 35: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Novel Blastococcus, Geodermatophilus and Modestobacter isolates from the extreme hyper arid Yungay soil

Arginine-vitamin agar Humic-acid-vitamin agar Oligotrophic agar R2A agar

ISP2ISP1 ISP3 ISP4

ISP5 ISP6 ISP7

Starch casein agar

Selective media

Modestobacter colour-group 46, 12 isolates

M. versicolor CP153-2T (AJ871304)

M. marinus 42H12-1T (EU181225)

M. roseus KLBMP 1279T ( JQ819258)

Modestobacter colour-group 45, 4 isolates

M. multiseptatus AA-826T (Y18646)

B. jejuensis KST3-10T (DQ200983)

B. endophyticus YIM 68236T (GQ494034)

B. aggregates ATCC 25902T (L40614)

Isolate KNN47

B. saxobsidens BC448T (AJ316571)

G. terrae PB261T (JN033773)

G. solani PB34T (JN033772)

G. taihuensis 3-wff-81T (JX294478)

G. normandii CF5/3T (HE654546)

G. telluris CF9/1/1T (HE815469)

G. saharensis CF5/5T (HE654551)

G. arenarius CF5/4T (HE654547)

G. nigrescens YIM 75980T (JN656711)

G. ruber CPCC 201356T (EU438905)

G. obscurus DSM 43160T (CP001867)

G. siccatus CF6/1T (HE654548)

Isolate KNN44-3

Isolate KNN44-1

Isolate KNN44-4

99

100

92

87

94

79

100

92

51

98

95

99

77

54

86

76

87

8499

58

7879

0.005

**

***

*

*

*

ML

*

**

**

*

* **

**

Page 36: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Novel Micromonospora isolates from the extreme hyper-arid Lomas Bayas soil

http://www0.nih.go.jp/saj/DigitalAtlas2/

Isolate LB-1 GZ-4

Isolate LB-1 IS-10

Micromonospora saelicesensis Lupac 09T(AJ783993)

Isolate LB-1 R2-3

Isolate LB-1 SC-4Micromonospora chokoriensis 2-19/6T(AB241454)

Micromonospora lupini lupac 14NT(AJ783996)

Micromonospora mirobrigensis WA201T(AJ626950)

Micromonospora purpureochromogenes DSM 43821T(X92611)

Micromonospora aurantiaca ATCC 27029T(CP002162)

Micromonospora marina JSM1-1T(AB196712)

Micromonospora humi P0402T(GU459068)

Micromonospora tulbaghiae TVU1T(EU196562)Isolate LB-1 SC-7

Micromonospora chalcea DSM 43026T(X92594)64

99

*

86

91

91

58

95

81 95

58

0.002

*

**

***

*

**

Page 37: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Actinobacterial Genera Isolated from the Sampling Sites

Salar de Atacama(Hyper-arid soil)

ALMA(Hyper-arid soil)

Yungay

(Extreme hyper-arid soil)

Lomas Bayas

(Most extreme hyper-arid soil)

*Actinomadura+ Amycolatopsis

*Kribbella

*Lechevalieria

*Nocardiopsis

*Nonomuraea

*Saccharothrix+Streptomyces

*Actinomadura+Amycolatopsis

*Cryptosporangium

*Nocardia

*Pseudonocardia+Streptomyces

*Blastococcus

*Couchioplanes

*Geodermatophilus

*Kribbella

*Modestobacter

*Pseudonocardia+Streptomyces

*Actinocorralia

*Micromonospora+Streptomyces

*Novel members of rare and +established genera.

Members of 17 genera isolated to date.

Page 38: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Dereplication of Isolates and Preparation of Extracts for Chemical

Screening

Representatives of colony types taken from isolation plates.

Rapid assignment of isolates to colour-groups.

Selection of isolates showing bioactivity in plug assays.

Choice of creative isolates that form distinct 16S rRNA gene

lineages.

Growth of selected isolates on production media.

Preparation of extracts for chemical screening.

Many

Fewer

Few

Page 39: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Media for Submerged Culture of Selected Novel Isolates

Medium 19: enhances production of novel drug leads from Streptomyces

species.

Medium 410: promotes optimal growth and production of drug

candidates from filamentous actinobacterial genera.

Starch-casein broth: supports growth of most streptomycetes.

Yeast extract-malt extract broth (ISP medium 2): promotes production

of novel drug leads from filamentous actinobacteria.

Choice of production media for the expression of specialised metabolites is

heavily dependent on assignment of isolates to the correct taxa.

Page 40: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

MR289_KNN64_5_ISP2 #248 RT: 8.23 AV: 1 NL: 2.07E5 microAU

200 220 240 260 280 300 320 340 360 380 400

wavelength (nm)

0

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

Re

lative

Ab

so

rba

nce

226.00

279.00

336.00

394.00

MR289_KNN64_5_ISP2 #288 RT: 9.57 AV: 1 NL: 1.64E5 microAU

200 220 240 260 280 300 320 340 360 380 400

wavelength (nm)

0

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

Re

lative

Ab

so

rba

nce

228.00

284.00

339.00

393.00

MR289_KNN64_5_ISP2 #310 RT: 10.30 AV: 1 NL: 1.36E5 microAU

200 220 240 260 280 300 320 340 360 380 400 420

wavelength (nm)

0

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

Re

lative

Ab

so

rba

nce

227.00

354.00

265.00

394.00

MR289_KNN64_5_ISP2 #364 RT: 12.10 AV: 1 NL: 1.23E5 microAU

200 220 240 260 280 300 320 340 360 380 400

wavelength (nm)

0

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

Re

lative

Ab

so

rba

nce

227.00

336.00

352.00

RT: 0.00 - 30.00

0 5 10 15 20 25 30

Time (min)

0

10000

20000

30000

40000

50000

60000

70000

80000

90000

100000

110000

120000

130000

140000

150000

160000

170000

180000

190000

uAU

6.67

0.50

7.07

9.576.23

5.47 10.30

4.53 12.102.97

26.0012.302.07 25.7323.9022.00

14.00 17.53

26.43 29.77

NL:1.92E5

Total Scan PDA MR289_KNN64_5_ISP2

UV trace

UV trace

UV traceUV trace

LCMS analysis of metabolite extract from

Streptomyces isolate KNN64-5 after shaking in ISP2

broth for 14 days at 28oC.

Strain KNN64-5 produces 5-6 derivatives of novel aromatic or polyene

compounds. The strain was isolated from the Salar de Atacama soil and forms a

distinct branch in the S. fimbriatus 16S rRNA gene clade.

MS trace

Page 41: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

LCMS analysis of metabolite extract from Amycolatopsis ruanii KNN50-8 after

shaking in medium 19 broth for 14 days at 28oC.

Strain KNN50-8 produces major and minor specialised novel metabolites. The

strain was isolated from the hyper-arid Salar de Atacama.

Major new metabolite

UV spectrum of the major metabolite

Page 42: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Pathogen B. subtilis E. coli P. fluorescens S. aureus S. cerevisiae

ALMA 52.2 11.5 21.2 30 60

Lomas Bayas 18.8 0 4.7 23.4 15.6

Primary Screening of ALMA and Lomas Bayas Isolates against

Panel of Pathogens

Percentage of the 132 actinbacteria that showed antimicrobial activity

against pathogens

• The 16 isolates that showed activity against the Escherichia coli strain were

selected for further study.

Page 43: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

LCMS analysis of metabolite extract from Streptomyces isolate H9 after shaking in

starch-casein broth for 14 days at 28oC

• The strain was isolated from ALMA site 4 (4000 m surface soil) on Gause’s No.1 broth after 14

days at 28oC

• Streptomyces isolate H9 produces novel specialised metabolites belonging to diverse chemical

scaffolds.

Page 44: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

• The strain was isolated from ALMA site 6 (5000 m subsurface soil) on Guase’s No.1 agar after

14 days at 28oC

• Lechevalieria isolate H45 produces specialised metabolites belonging to diverse novel chemical

scaffolds.

LCMS analysis of metabolite extract from Lechevalieria isolate H45 after shaking

in medium 410 broth for 14 days at 28oC

Page 45: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Neighbour–joining tree based on almost complete 16S rRNA gene sequences showing relationships between (A)

Streptomyces isolate H9 and closely related Streptomyces type strains and (B) Lechevalieria isolate 45and the type strains of its nearest neighbours. Asterisks (*) indicate branches of the tree that were recovered with

the maximum-likelihood and maximum-parsimony tree-making algorithms.

Phylogenetic Analyses

B

A

Page 46: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

46J O N G S I K C H U N L A B . S E O U L N A T I O N A L U N I V .

Released Genomes in National Center for Biotechnology Information (NCBI)

(1995-2014)15,842 genomes (as of January 2014)

0

1000

2000

3000

4000

5000

6000

7000

8000

NGS

>7,000 genomes

In 2013

GENOMICS

Page 47: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

47J O N G S I K C H U N L A B . S E O U L N A T I O N A L U N I V .

Genomics for Systematics:

The Present Status

Species with valid

names

Species with 16S rRNA

gene sequence (type

strain)

Species with genome

sequence

Species with genome

sequence (type strain)

Bacteria 11,275 10,887 2,951 2,085

Archaea 429 423 179 165

Total

(Prokaryotes)11,704 11,310 3,130 2,250

Percent 100% 96.6% 26.7% 19.2%

We need a strategy for describing all of the prokaryotes (~ 1 million

species), not just the small fraction that have been cultivated.

Page 48: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Modestobacter Isolate ASC16 Streptomyces leeuwenhoekii C34T

Preliminary Analysis of Whole Genome Sequence Data

Habitat: isolated from the extreme hyper-arid Yungay soil

Genomic size: ~ 5.57 Mb

G+C content: 74.1%

Protein coding genes: 5,445

Secondary metabolite profile : few predicted biosynthetic gene

clusters

Stress genes: resistance to UV radiation and desiccation

Spore forming genes: present

Habitat: isolated from hyper-arid Salar de Atacama soil

Genomic size: ~ 8.66 Mb

G+C content: 72.1%

Protein coding genes: ~7,800

Secondary metabolic profile: 31 predicted biosynthetic gene

clusters including one for chaxamycins

Stress genes: present

Spore forming genes: present

Page 49: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Culture Independent Studies based on Pyrosequencing

Family Genera

Actinoplanaceae Couchioplanes

Cellulomonadaceae Actinotalea, Cellulomonas, Oerskovia

Cryptosporangiaceae Cryptosporangium

Dietziaceae Dietzia

Geodermatophilaceae Blastococcus, Geodermatophilus, Modestobacter

Glycomycetaceae Glycomyces

Microbacteriaceae Agrococcus, Agromyces, Microbacterium, Rathayibacter

Micrococcaceae Micrococcus

Micromonosporaceae Actinoplanes, Catellatospora, Microbiospora, Micromonospora, Pilimelia,

Virgisporangium

Nocardiaceae Nocardia, Rhodococcus

Nocardioidaceae Aeromicrobium, Friedmanniella, Kribbella, Nocardioides, Pimelobacter

Nocardiopsaceae Nocardiopsis

Pseudonocardiaceae Actinomycetospora, Amycolatopsis, Lechevalieria, Lentzea, Pseudonocardia,

Saccharothrix

Streptomycetaceae Streptomyces

Streptosporangiaceae Acrocarpospora, Nonomuraea

Thermomonosporaceae Actinoallomurus, Actinocorallia, Actinomadura

* Genera isolated classified using culture dependent approaches are marked in bold

Primary analysis suggests that there are at least 97 different genera in the soil samples, as exemplified below:

Page 50: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Key Conclusions

• Atacama Desert soils contain novel filamentous actinobacteria with

the ability to synthesise new specialised metabolites.

• Natural product hits enhanced by dereplication of isolates and

extracts.

• Distribution of actinobacterial taxa provide insights into their

taxonomic roles.

• Further support for the taxonomic approach to drug discovery.

HENCE NEED FOR HIGHLY TRAINED MICROBIAL

SYSTEMATISTS.

Page 51: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Some New Directions of Travel• Community DNA extracted from different habitats to determine extent of actinobacterial

diversity in Atacama Desert soils.

• Innovative and rapid selective isolation methods needed to isolate and recognise rare and

neglected taxa present in environmental samples.

• Improved methods required for the expression of natural product gene clusters.

• Structural analyses of interesting bioactive compounds.

• Polyphasic taxonomy of novel creative isolates.

• Establish the extent of coupling between taxonomic and chemical diversity.

• Focus on creative novel strains for systems and synthetic biology.

• Search for adaptive genes and drivers of actinobacterial speciation in Atacama Desert soils.

Page 52: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Acknowledgements

Juan Asenjo and Barbara Andrews, University of Chile, Santiago, Chile.

Luis Cáceres, University of Antofagasta, Chile.

Jungsik Chun, Seoul National University, Korea.

Genevieve Girard and Gilles van Wezel, Leiden University, The Netherlands.

David Labeda, USDA-ARS, Peoria, USA.

Marcel Jaspars, Aberdeen University, Scotland.

Barny Whitman, University of Georgia, USA.

Ros Brown, Kanungnid Busarakam and Hamidah Idris, Newcastle University, England.

And for support from the Leverhulme Trust and

The Royal Society.

Page 53: Successful Drug Discovery Informed by AB-18-032 mAU ... · • A phylogenetically defined, metabolically active group of slow-growing, gram-positive bacteria which have DNA rich in

Thank You